300
- Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet.
2013;382(9904):1587–99. - Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, et al. Risk of colorectal
high-grade dysplasia and cancer in a prospective observational cohort of patients with inflam-
matory bowel disease. Gastroenterology. 2013;145(1):166–75.e8. - Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and
management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology.
2010;138(2):746–74. 74 e1-4; quiz e12-3 - Gaidos JK, Kane SV. Overcoming challenges of treating inflammatory bowel disease in preg-
nancy. Expert Rev. Clin Immunol. 2016;12(8):871–8. - Russell RK, Hansen R, Turner D. New treatments for ulcerative colitis: do we have pediatric
data? Expert Rev. Clin Immunol. 2016;12(7):701–4. - Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, et al. The relationship
between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s
disease. Gut. 2015;64(10):1539–45. - Li H, Kock K, Wisler JA, Rees WA, Prince PJ, Reynhardt KO, et al. Prediction of clinical
pharmacokinetics of AMG 181, a human anti-alpha 4 beta 7 monoclonal antibody for treating
inflammatory bowel diseases. Pharmacol Res Perspect. 2015;3(1):e00098. - Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal
addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised
study. Gut. 2011;60(8):1068–75. - Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A ran-
domised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis.
Gut. 2013;62(8):1122–30. - Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for
induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76. - Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous goli-
mumab induces clinical response and remission in patients with moderate-to-severe ulcerative
colitis. Gastroenterology. 2014;146(1):85–95. quiz e14-5 - Feagan BG, Sandborn WJ, D'Haens G, Pola S, McDonald JW, Rutgeerts P, et al. The role of
centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative
colitis. Gastroenterology. 2013;145(1):149–57.e2. - Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, et al. Association between
response to etrolizumab and expression of integrin alphaE and granzyme a in colon biopsies of
patients with ulcerative colitis. Gastroenterology. 2016;150(2):477–87.e9. - Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, et al. Phase I safety and
pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleo-
tide (ISIS 2302). J Pharmacol Exp Ther. 1997;282(3):1173–80. - Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A
placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s dis-
ease. Gastroenterology. 1998;114(6):1133–42. - Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind,
placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1
antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s
disease. Gut. 2002;51(1):30–6. - Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of effi-
cacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease.
Gastroenterology. 2001;120(6):1339–46. - van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose
study of alicaforsen enema in active ulcerative colitis. Gut. 2004;53(11):1646–51. - Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, et al. Bioavailability and thera-
peutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects
with active ulcerative colitis. Aliment Pharmacol Ther. 2006;23(10):1427–34.
J.K. Limdi and F.A. Farraye